Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.64 |
| ▸ | TUBB | P07437 | 1/20 | 0.64 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.64 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.64 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.64 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.64 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.64 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.64 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.64 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.64 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.64 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.64 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.64 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.64 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12297776 | 0.84 | MEN1 (0.59) | ALOX5NPC1RAB9AMAPTMMP12 | |
| SCHEMBL6199558 | 0.83 | CYP1A1 (0.61) | NPC1RAB9AMAPTMMP12MEN1 | |
| SCHEMBL28117025 | 0.80 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12297303 | 0.79 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hydrochloric Acid SCHEMBL8524166 | 0.78 | MAPT (0.70) | NPC1RAB9AMAPTMMP12MEN1 | |
| SCHEMBL12297173 | 0.77 | TUBB4A (0.80) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28331467 | 0.77 | TUBB4A (0.88) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18114158 | 0.76 | SMN1; SMN2 (0.63) | NPC1RAB9AMAPTMMP12MEN1 | |
| SCHEMBL13224475 | 0.76 | ALOX5 (0.58) | ALOX5NPC1RAB9AMAPTMMP12 | |
| SCHEMBL26136074 | 0.76 | MEN1 (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | TUBB4A 235/4885TUBB 206/4885TUBA3C 832/4885 |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | TUBB4A 235/4885TUBB 206/4885TUBA3C 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.